NewAmsterdam Pharma Company NVNASDAQ:NAMS
- LAST PRICE18.0300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots14.5600/ 1
- Ask / Lots28.6600/ 1
- Open / Previous Close--- / 18.0300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NAMS |
|---|---|---|
| 09:32 ET | 1175 | 17.87 |
| 09:33 ET | 100 | 17.55 |
| 09:35 ET | 200 | 17.54 |
| 09:37 ET | 300 | 17.275 |
| 09:39 ET | 2106 | 17.47 |
| 09:42 ET | 500 | 17.19 |
| 09:44 ET | 240 | 17.16 |
| 09:46 ET | 100 | 17.27 |
| 09:48 ET | 1997 | 17.71 |
| 09:50 ET | 1481 | 17.22 |
| 09:53 ET | 830 | 17.78 |
| 09:55 ET | 200 | 17.73 |
| 09:57 ET | 200 | 17.5 |
| 10:00 ET | 300 | 17.72 |
| 10:02 ET | 300 | 17.5225 |
| 10:06 ET | 300 | 17.72 |
| 10:08 ET | 400 | 17.72 |
| 10:09 ET | 300 | 17.72 |
| 10:11 ET | 100 | 17.7 |
| 10:13 ET | 300 | 17.72 |
| 10:15 ET | 100 | 17.75 |
| 10:18 ET | 200 | 17.75 |
| 10:20 ET | 1002 | 17.72 |
| 10:22 ET | 1360 | 17.835 |
| 10:24 ET | 200 | 17.7 |
| 10:26 ET | 100 | 17.835 |
| 10:27 ET | 620 | 17.87 |
| 10:31 ET | 100 | 17.89 |
| 10:33 ET | 100 | 17.815 |
| 10:36 ET | 200 | 17.93 |
| 10:40 ET | 100 | 17.945 |
| 10:44 ET | 300 | 18.13 |
| 10:45 ET | 100 | 18.14 |
| 10:47 ET | 1200 | 18.13 |
| 10:49 ET | 400 | 18.255 |
| 10:54 ET | 100 | 18.28 |
| 10:56 ET | 100 | 18.165 |
| 10:58 ET | 400 | 18.27 |
| 11:00 ET | 300 | 18.31 |
| 11:02 ET | 513 | 18.3 |
| 11:03 ET | 100 | 18.29 |
| 11:05 ET | 300 | 18.29 |
| 11:09 ET | 400 | 18.3 |
| 11:12 ET | 200 | 18.285 |
| 11:14 ET | 200 | 18.175 |
| 11:16 ET | 100 | 18.29 |
| 11:18 ET | 100 | 18.26 |
| 11:20 ET | 100 | 18.24 |
| 11:21 ET | 100 | 18.16 |
| 11:23 ET | 100 | 18.235 |
| 11:25 ET | 200 | 18.16 |
| 11:27 ET | 100 | 18.2 |
| 11:30 ET | 400 | 18.29 |
| 11:32 ET | 400 | 18.36 |
| 11:34 ET | 100 | 18.53 |
| 11:36 ET | 100 | 18.52 |
| 11:38 ET | 100 | 18.42 |
| 11:39 ET | 500 | 18.42 |
| 11:41 ET | 1800 | 18.3 |
| 11:45 ET | 100 | 18.13 |
| 11:48 ET | 100 | 18.28 |
| 11:50 ET | 200 | 18.24 |
| 11:52 ET | 200 | 18.225 |
| 11:54 ET | 100 | 18.22 |
| 12:01 ET | 200 | 18.1175 |
| 12:03 ET | 100 | 18.115 |
| 12:12 ET | 100 | 18.115 |
| 12:14 ET | 100 | 18.075 |
| 12:15 ET | 100 | 18.07 |
| 12:17 ET | 100 | 18.095 |
| 12:19 ET | 100 | 18.06 |
| 12:21 ET | 200 | 18.16 |
| 12:24 ET | 200 | 18.12 |
| 12:28 ET | 100 | 18.18 |
| 12:32 ET | 400 | 18.18 |
| 12:33 ET | 552 | 18.13 |
| 12:37 ET | 300 | 18.22 |
| 12:39 ET | 100 | 18.31 |
| 12:48 ET | 200 | 18.21 |
| 12:50 ET | 100 | 18.21 |
| 12:53 ET | 442 | 18.2 |
| 12:55 ET | 100 | 18.24 |
| 01:02 ET | 100 | 18.29 |
| 01:04 ET | 2477 | 18.19 |
| 01:09 ET | 222 | 18.21 |
| 01:13 ET | 100 | 18.185 |
| 01:15 ET | 100 | 18.185 |
| 01:18 ET | 200 | 18.16 |
| 01:20 ET | 800 | 18.33 |
| 01:24 ET | 200 | 18.32 |
| 01:26 ET | 218 | 18.35 |
| 01:31 ET | 100 | 18.315 |
| 01:38 ET | 200 | 18.31 |
| 01:47 ET | 100 | 18.3 |
| 01:49 ET | 100 | 18.27 |
| 01:51 ET | 200 | 18.26 |
| 01:54 ET | 800 | 18.21 |
| 01:58 ET | 100 | 18.28 |
| 02:00 ET | 100 | 18.22 |
| 02:05 ET | 200 | 18.22 |
| 02:09 ET | 300 | 18.2275 |
| 02:14 ET | 100 | 18.27 |
| 02:16 ET | 200 | 18.215 |
| 02:18 ET | 497 | 18.2175 |
| 02:20 ET | 644 | 18.27 |
| 02:21 ET | 100 | 18.28 |
| 02:23 ET | 300 | 18.3 |
| 02:25 ET | 1100 | 18.3 |
| 02:27 ET | 100 | 18.235 |
| 02:32 ET | 300 | 18.17 |
| 02:36 ET | 1104 | 18.22 |
| 02:39 ET | 259 | 18.22 |
| 02:41 ET | 100 | 18.23 |
| 02:43 ET | 200 | 18.14 |
| 02:45 ET | 100 | 18.175 |
| 02:48 ET | 400 | 18.175 |
| 02:56 ET | 200 | 18.16 |
| 02:57 ET | 300 | 18.17 |
| 03:01 ET | 100 | 18.13 |
| 03:03 ET | 200 | 18.125 |
| 03:06 ET | 400 | 18.18 |
| 03:08 ET | 1787 | 18.145 |
| 03:12 ET | 922 | 18.185 |
| 03:14 ET | 100 | 18.21 |
| 03:15 ET | 100 | 18.29 |
| 03:17 ET | 200 | 18.29 |
| 03:21 ET | 200 | 18.27 |
| 03:26 ET | 830 | 18.16 |
| 03:28 ET | 100 | 18.17 |
| 03:30 ET | 728 | 18.23 |
| 03:32 ET | 100 | 18.22 |
| 03:33 ET | 1000 | 18.2 |
| 03:35 ET | 690 | 18.19 |
| 03:37 ET | 696 | 18.14 |
| 03:42 ET | 2004 | 18.19 |
| 03:44 ET | 1420 | 18.2 |
| 03:46 ET | 100 | 18.135 |
| 03:48 ET | 300 | 18.2 |
| 03:51 ET | 200 | 18.125 |
| 03:53 ET | 1412 | 18.035 |
| 03:55 ET | 1116 | 17.9 |
| 03:57 ET | 4723 | 17.95 |
| 04:00 ET | 46213 | 18.03 |
Nov 1, 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 5:26PM ET on Friday Nov 01, 2024 by Dow Jones
5:26PM ET on Friday Nov 01, 2024 by Dow Jones
Oct 28, 2024
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November, from 4:30PM ET on Monday Oct 28, 2024 by Dow Jones
4:30PM ET on Monday Oct 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NewAmsterdam Pharma Company NV | 1.6B | -6.8x | --- |
Bicycle Therapeutics PLC | 1.6B | -7.1x | --- |
Syndax Pharmaceuticals Inc | 1.6B | -5.6x | --- |
Celldex Therapeutics Inc | 1.7B | -9.3x | --- |
Tarsus Pharmaceuticals Inc | 1.8B | -10.4x | --- |
Rocket Pharmaceuticals Inc | 1.5B | -6.0x | --- |
Company Information
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Contact Information
- Headquarters
- Gooimeer 2-35NAARDEN, Netherlands 1411 DC
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- William Lewis
- Chief Executive Officer, Executive Director
- Michael Davidson
- Interim Chief Financial Officer
- Louise Kooij
- Chief Operating Officer
- Douglas Kling
- Chief Scientific Officer, Non-Executive Director
- John Kastelein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
|---|---|
Revenue (TTM) | $7.4M |
Shares Outstanding | 90.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.00 |
EPS | $-2.64 |
Book Value | $3.50 |
P/E Ratio | -6.8x |
Price/Sales (TTM) | 218.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,792.90% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
